Meihua International Medical Technologies Co Ltd (MHUA)vsNovartis AG ADR (NVS)
MHUA
Meihua International Medical Technologies Co Ltd
$7.61
0.00%
HEALTHCARE · Cap: $425.43M
NVS
Novartis AG ADR
$153.27
+0.76%
HEALTHCARE · Cap: $291.32B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 63210% more annual revenue ($56.69B vs $89.55M). NVS leads profitability with a 22.5% profit margin vs 10.3%. MHUA trades at a lower P/E of 0.3x. NVS earns a higher WallStSmart Score of 51/100 (C-).
MHUA
Avoid34
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MHUA.
Margin of Safety
-66.5%
Fair Value
$92.73
Current Price
$153.27
$60.54 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Weak financial health signals
Revenue declined 16.2%
Earnings declined 42.0%
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : MHUA
The strongest argument for MHUA centers on P/E Ratio, Price/Book, Debt/Equity.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : MHUA
The primary concerns for MHUA are Market Cap, Piotroski F-Score, Revenue Growth.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
MHUA profiles as a declining stock while NVS is a value play — different risk/reward profiles.
MHUA carries more volatility with a beta of 0.75 — expect wider price swings.
NVS is growing revenue faster at 0.8% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 34/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Meihua International Medical Technologies Co Ltd
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Meihua International Medical Technologies Co., Ltd. is engaged in the manufacturing and marketing of medical consumables in the People's Republic of China.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?